Abstract-Brain renin-angiotensin system hyperactivity has been implicated in the development and maintenance of hypertension. We have shown that aminopeptidase A is involved in the formation of brain angiotensin III, which exerts tonic stimulatory control over blood pressure in hypertensive deoxycorticosterone acetate-salt rats and spontaneously hypertensive rats. We have also shown that injection of the specific and selective aminopeptidase A inhibitor, (3S)-3-amino-4-sulfanyl-butane-1-sulfonic acid (EC33), by central route or its prodrug, RB150/firibastat, by oral route inhibited brain aminopeptidase A activity and blocked the formation of brain angiotensin III, normalizing blood pressure in hypertensive rats. These findings identified brain aminopeptidase A as a potential new therapeutic target for hypertension. We report here the development of a new aminopeptidase A inhibitor prodrug, NI956/QGC006, obtained by the disulfide bridgemediated dimerization of NI929. NI929 is 10× more efficient than EC33 at inhibiting recombinant mouse aminopeptidase A activity in vitro. After oral administration at a dose of 4 mg/kg in conscious deoxycorticosterone acetate-salt rats, NI956/QGC006 normalized brain aminopeptidase A activity and induced a marked decrease in blood pressure of −44±13 mm Hg 4 hours after treatment (P<0.001), sustained over 10 hours (−21±12 mm Hg; P<0.05). Moreover, NI956/ QGC006 decreased plasma arginine-vasopressin levels, and increased diuresis and natriuresis, that may participate to the blood pressure decrease. Finally, NI956/QGC006 did not affect plasma sodium and potassium concentrations. This study shows that NI956/QGC006 is a best-in-class central-acting aminopeptidase A inhibitor prodrug. Our results support the development of hypertension treatments targeting brain aminopeptidase A.
H igh blood pressure (BP) is a major cardiovascular risk factor. 1 Hypertension currently affects 34% of the adult population in the United States, and its prevalence is increasing, together with that of obesity and diabetes mellitus. 2 Several pharmacological treatments, including systemic renin-angiotensin system (RAS) blockers, calcium-channel blockers, and diuretics, are available for BP control. They act by decreasing vascular resistance, increasing renal sodium output, or decreasing extracellular volume. However, monotherapy is ineffective in more than 50% of cases, and most hypertensive patients require 2 or more antihypertensive drugs to control BP. 3 Moreover, the overall incidence of hypertension resistant to at least 3 antihypertensive drugs (including a diuretic) has been estimated at 15% of the hypertensive population in the United States. 4 There is, therefore, a need to develop new classes of antihypertensive agents acting on new targets, with diversified modes of action, to improve BP control.
Brain RAS hyperactivity has been implicated in the development and maintenance of hypertension in several experimental and genetic animal models of hypertension, such as spontaneously hypertensive rats, deoxycorticosterone acetate (DOCA)-salt rats, and transgenic mice overexpressing both angiotensinogen and renin human genes. [5] [6] [7] [8] [9] [10] [11] All known components of the RAS, including the precursor and enzymes required for the production and metabolism of angiotensin peptides and specific AT 1 (angiotensin type 1) and AT 2 (angiotensin type 2) receptors, have been identified in the brain (reviewed in Xu et al 10 , Marc et al 11 , and Saavedra 12 ). We previously reported that the brain APA (aminopeptidase A, EC 3.4.11.7), a membrane-bound zinc metalloprotease, generates Ang III (angiotensin III) from Ang II (angiotensin II) and that APN (aminopeptidase N, EC 3.4.11.2), another zinc metalloprotease, metabolizes Ang III into Ang IV (angiotensin IV).
interact with AT 1 receptors, thereby increasing BP and arginine vasopressin (AVP) release. 12, 13, 14, 15, 16 We first developed specific and selective APA and APN inhibitors: (3S)-3-amino-4-sulfanyl-butane-1-sulfonic acid (EC33) and (2S)-2-amino-4-methylsulfanyl butane thiol (PC18), respectively. 17, 18 We used these molecules to demonstrate that Ang III, and not Ang II as in the periphery, is one of the main effector peptides of the brain RAS in the control of BP and AVP release. 7, 8, 15, 19, 20 Brain Ang III exerts tonic stimulatory control over BP in 2 experimental models of hypertension: spontaneously hypertensive rat, a model of essential hypertension sensitive to RAS blockers, 19, 21 and DOCA-salt 8, 11, 22 rats, a salt-and volume-dependent model of hypertension. Brain APA, the enzyme responsible for generating brain Ang III, therefore, constitutes a promising target for hypertension treatment, justifying the development of potent and selective APA inhibitors as central-acting antihypertensive agents. We developed a first-in-class prodrug of EC33, RB150 (4,4-dithio [bis{(3S)-3-aminobutyl sulfonic acid}]), composed of 2 molecules of EC33 linked by a disulfide bridge. 8, 23 Orally administered RB150/firibastat crosses the intestinal, hepatic, and blood-brain barriers, entering the brain, where the disulfide bridge is immediately cleaved by brain reductases to generate 2 active molecules of EC33, which inhibit brain APA activity, block the formation of brain Ang III, and decrease BP and AVP release in alert hypertensive rats. 8, 11, 21, 22 However, the high dose of orally active RB150/firibastat required to decrease BP in spontaneously hypertensive rat (150 mg/kg) 21 and DOCA-salt (50 mg/kg) 11 rats led us to develop new more potent APA inhibitor prodrugs with greater bioavailability for inhibiting brain APA activity. We developed a nonpeptidic APA inhibitor, NI929 ([3S,4S]-3-amino-4-mercapto-6-phenyl-hexane-1-sulfonic acid), that is 10×more potent than EC33 at inhibiting recombinant mouse APA activity in vitro (K i value of 30 nmol/L). 24 In the current study, we designed NI956, a new APA inhibitor prodrug obtained by disulfide bridge-mediated dimerization of NI929. Our aim was to investigate whether NI956 is an orally active best-in-class APA inhibitor prodrug. For this purpose, we explored the mode of NI929 binding to APA and compared it to EC33 binding. We evaluated the ability of orally administrated NI956 to decrease brain APA activity and arterial BP in conscious DOCA-salt hypertensive rats, relative to normotensive Wistar Kyoto (WKY) rats. We analyzed the mechanism of action of NI956 to decrease BP by measuring the effects of orally administrated NI956 on systemic AVP release, diuresis, and natriuresis. Finally, we examined whether NI956 treatment modified plasma potassium concentration because different classes of antihypertensive agents have been reported to lead in some cases to plasma potassium imbalance and sudden death.
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Materials and Methods
The authors declare that all supporting data are available within the article in the online-only Data Supplement.
Synthesis of NI956
The synthesis of NI956 is described in the online-only Data Supplement.
Molecular Docking and Molecular Dynamics Simulations
The NI929 docking and simulation protocols are detailed in the online-only Data Supplement.
Ethics
Animal care and surgical procedures were performed according to Directive 2010/63/EU of the European Parliament, approved by the French Ministry of Agriculture. The project was submitted to the appropriate ethics committee and authorization was obtained: CEEA No 59, reference number 01962.01.
Animals
Ten-week-old male DOCA-salt and WKY rats were purchased from Charles River Laboratories (L'Arbresle, France). Animals were randomly assigned in each group with allocation concealment, and blinding procedures were used with coding system. Animal housing and euthanasia are described in the online-only Data Supplement.
Prodrug Preparation
NI956 administered by intracerebroventricular, intravenous, or per os routes was dissolved in sterile 0.9% NaCl pH 7.4. In vivo, NI956 was administered intracerebroventricularly at a dose of 25 µg in 10 µL, intravenously into the femoral vein at a dose of 0.3 to 15 mg/kg in 400 µL, or per os by gavage at a dose of 4 mg/kg in 400 µL.
Enzymatic Activity Measurements
The enzymatic activities of APA and APN in vitro were determined as detailed in the online-only Data Supplement.
Surgical Methods
Surgical Methods are detailed in the online-only Data Supplement.
Mean Arterial BP Recording
Baseline mean arterial BP (MABP) was recorded for at least 60 minutes before drug administration by the intravenous or oral route. A single dose of NI956 was then administered intravenously (0.3, 1, 2, 4, or 15 mg/kg) or orally (4 mg/kg) in a volume of 400 µL. MABP was recorded continuously for 6 hours after treatment. MABP was also recorded for 60 minutes, 24 hours after administration, to check BP stability.
AVP Radioimmunoassay
Plasma was acidified by adding 0.2 volumes of 3 mol/L HCl and was then stored at −80°C until the AVP assay, as described in the onlineonly Data Supplement.
Urine and Electrolyte Output Measurements
Urine and electrolyte output measurements are described in the online-only Data Supplement.
In Vitro Pharmacological Profile
Binding, enzymatic, and uptake assays are detailed in the online-only Data Supplement.
Statistical Analysis
Quantitative data are shown as means, with error bars indicating the SEM. Statistical analysis is detailed in the online-only Data Supplement.
Results
Synthesis of NI956
APA and APN are involved in the metabolism of Ang II and Ang III, respectively. The prodrug NI956 is composed of 2 molecules of the APA inhibitor NI929 linked by a disulfide bridge ( Figure 1 ). NI929 interacts with the S1 and S′1 subsites of the APA active site ( Figure 1 ).
The synthesis of NI929 and NI956 was originally described by Roques et al (PCT application WO2005014535). The synthesis has been modified slightly to increase global yield and to control the absolute configuration (3S and 4S) of the most active enantiomer (NI929 or compound 5e 2 ), as described in the online-only Data Supplement.
Prediction of the Mode of NI929 Binding to APA
We investigated the mode of NI929 binding to APA by performing molecular docking followed by molecular dynamics simulations and Molecular Mechanics/Poisson-Boltzmann Surface Area continuum solvation calculations. 28 As expected, the interactions of the sulfonate, amine, and thiol groups of NI929 were as reported for the EC33 inhibitor. 29 The sulfonate interacted with Arg887 and the calcium ion; the amine interacted with the glutamate triad, Glu223, Glu360, and Glu416; and the thiol interacted with the zinc ion ( Figure 2A ). The phenolic ring, which would interact in the S1′ subsite, was predicted to engage in π-alkyl interactions with the Val390 residue ( Figure 2A ). However, the position of the hydrophobic groups of Tyr479 and Thr356 was also relatively close to the phenolic ring of NI929 (Figure 2A ), suggesting that it might be possible to improve the mode of binding.
We refined the binding mechanism by performing unrestrained all-atoms molecular dynamics simulations on the human APA/NI929 complex. This simulation allowed major sidechain movements, which improved accommodation of the phenolic ring of NI929. By screening the simulation frames with the lowest total free energy according to the Molecular Mechanics/Poisson-Boltzmann Surface Area method ( Figure  S1A in the online-only Data Supplement), we identified a conformation in which NI929 simultaneously established π-alkyl and T-shaped π-stack interactions with residues Val390 and Tyr479, respectively ( Figure 2B ). The methyl group from Thr356 also seems to be important to the hydrophobic environment, as this residue was involved in hydrophobic interactions throughout most of the simulation ( Figure S1B ). Other sporadic interactions involving Met359, His393, and Phe474 were also observed ( Figure S1B ).
Ability of NI956 to Inhibit Recombinant Purified APA
In vitro studies on recombinant purified mouse APA showed that the inhibitory potency of the reduced form of NI956 obtained in the presence of dithiothreitol (K i =3.1±0.5×10 −8 mol/L; Figure S2A ) was 10× greater than that recorded for EC33 (K i =3.0±0.1×10 −7 mol/L). 8 These results are consistent with the reported inhibitory potency of NI929 (K i =3.0×10 −8 mol/L). 24 Moreover, in the presence of dithiothreitol, a reagent that cleaves the disulfide bridge, NI956 had no effect on APN activity (K i >10 −5 mol/L; Figure S2B ). In the absence of dithiothreitol, the sulfide bridge was intact, and NI956 and RB150/ firibastat had no effect on APA and APN activity (K i >10 −5 mol/L). The concentration of dithiothreitol used was also inactive against APA. Importantly, NI956 did not inhibit other enzymes or receptors involved in BP control when tested at 10 −5 mol/L (Table S1 ).
NI956 Administration Decreased Brain APA Activity in Hypertensive DOCA-Salt Rats
We then explored the effect of NI956 in an experimental model of hypertension, the DOCA-salt rat, a salt-and volumedependent model of hypertension resistant to systemic RAS blockers. Brain APA activity in hypertensive DOCA-salt rats was significantly higher than in WKY rats (P<0.05; Figure 3 ). Brain APA activities in hypertensive DOCA-salt rats receiving administration of saline by intracerebroventricular, intravenous, or oral route were 114±8, 115±5, and 124±7 nmol of GluβNa hydrolyzed/mg prot per hour, respectively, and there was no significant difference between the distinct routes of administration. Brain APA activities in normotensive WKY rats receiving administration of saline by intracerebroventricular, intravenous, or oral route were 84±6, 82±9, and 81±5 nmol of GluβNa hydrolyzed/mg prot per hour, respectively, and there was no significant difference between the distinct routes of administration. The intracerebroventricular, intravenous, or oral administration of NI956 significantly inhibited brain APA activity 10 minutes after intracerebroventricular administration (P<0.0001) or 4 hours after intravenous/oral treatment (P<0.05; Figure 3 ). Brain APA activity in normotensive WKY rats did not decrease after the administration of NI956 by the intravenous or oral route, as shown by comparison with saline-treated WKY rats (nonsignificant; Figure 3 ).
NI956 Administration Decreased MABP in Hypertensive DOCA-Salt Rats
We plotted the curve of peak change in MAPB in conscious hypertensive DOCA-salt rats after the intravenous administration of saline or increasing doses of NI956 (0.3-15 mg/kg). The intravenous injection of NI956 decreased MABP in a dosedependent manner in DOCA-salt rats, with an ED 50 (median effective dose) of 0.53 mg/kg ( Figure 4A ). The oral administration of NI956 at 4 mg/kg in hypertensive DOCA-salt rats normalized MABP, reaching values similar to those in WKY rats ( Figure 4B and 4C), the maximal effect being observed at 4 hours (−44±13 mm Hg; P<0.001), persisting 10 hours after treatment (−21±12 mm Hg; P<0.05), and disappearing 24 hours after treatment ( Figure 4D ). No change in MABP was observed in normotensive WKY rats orally treated with NI956 ( Figure 4C ). The oral administration of NI956 had no effect on heart rate in DOCA-salt or WKY rats, regardless of the time elapsed between administration and recording ( Figure S3 ). No differences in MABP and heart rate were observed between oral and intravenous administration of NI956 given at the same dose (4 mg/kg; Figure 4B and Figure S3A ).
Oral NI956 Administration Decreased Plasma AVP Levels and Increased Diuresis and Natriuresis in Hypertensive DOCA-Salt Rats
Plasma AVP levels in hypertensive DOCA-salt rats were significantly higher than those in normotensive WKY rats (P<0.05; Figure 5A ). In DOCA-salt rats receiving oral NI956, plasma AVP levels decreased significantly after administration (P<0.05; Figure 5A ). Consistent with the MABP recorded in DOCA-salt rats, 24 hours after NI956 treatment, plasma AVP levels in DOCA-salt rats 24 hours after the administration of NI956 did not differ from those in DOCA-salt rats receiving saline ( Figure S4A ). Oral NI956 administration did not decrease plasma AVP levels in normotensive WKY rats relative to saline-treated WKY rats either 4 hours after administration ( Figure 5A ) or 24 hours after treatment ( Figure S4A ). We then evaluated the effects of NI956 administration on metabolic parameters in WKY and DOCA-salt rats. We found that diuresis, over a 5-hour period after acute treatment with NI956, increased in DOCA-salts rats (P<0.05; Figure 5B ). B, Pose obtained during unrestrained all-atom MD simulations, with selection on the basis of the lowest free energy structure, with the NI929 phenolic ring simultaneously interacting with Thr356, Val390, and Tyr479. The overall structure of APA is displayed as a cartoon representation in white, with residues from the active site displayed as sticks in cyan and labeled (larger labels indicate residues closer to the reader), the NI929 inhibitor is displayed in orange, and calcium and zinc ions are displayed as green and purple spheres, respectively. Distances between the hydrophobic moieties of Thr356, Val390, and Tyr479 to the center of the NI929 phenolic ring are also displayed. This increase in diuresis was accompanied by an increase in natriuresis (P<0.05; Figure 5C ). The oral administration of NI956 did not modify diuresis or natriuresis over a 5-hour period after treatment in WKY rats ( Figure 5B and 5C ). The oral administration of NI956 in WKY and DOCA-salt rats did not modify diuresis or natriuresis over a 24-hour period after treatment ( Figure S4B and S4C ).
Oral NI956 Administration Did Not Modify Plasma Sodium and Potassium Concentrations
We measured plasma sodium and potassium concentrations in WKY and DOCA-salt rats 4 and 24 hours after oral NI956 administration. NI956 did not affect either plasma sodium or plasma potassium concentrations in either normotensive WKY or hypertensive DOCA-salt rats (Table) . We also observed no change in plasma sodium and potassium concentrations in WKY and DOCA-salt rats 4 or 24 hours after the intravenous administration of NI956 (Table) .
Discussion
We describe here a new central-acting APA inhibitor prodrug, NI956, belonging to the same drug class as RB150/firibastat, that normalized BP after oral administration in a salt-dependent model of hypertension.
We previously developed RB150/firibastat, a prodrug of EC33, as an orally active antihypertensive agent targeting brain APA. 8, 11, 21, 22 Subsequently, to increase the potency and selectivity of EC33, which interacts only with the S1 subsite of APA, we incorporated on the EC33 scaffold an additional hydrophobic side chain, which was predicted to interact with the S1′ subsite of APA. This then resulted in the production of a nonpeptide APA inhibitor, NI929, with an inhibitory potency of 30 nmol/L against APA. 24 In the current study, for confirmation of the mode of binding of NI929, to both the S1 and S1′ subsites of APA, we docked this APA inhibitor into the refined human crystallographic structure of APA. 30 This molecular docking showed the same interactions of the sulfonate, amine and thiol groups of this compound in the S1 subsite as previously reported for EC33. 29 The phenolic ring, which was predicted to interact with the S1′ subsite, simultaneously established π-alkyl and T-shaped π-stack interactions with residues Val390 and Tyr479, respectively. These structural data account for the greater inhibitory potency and selectivity for APA of NI929 when compared with EC33. For APA inhibitors to be used as central antihypertensive agents, they must be able to cross the blood-brain barrier and inhibit the activity of brain APA after their oral administration. The central bioavailability of thiol inhibitors of zinc metallopeptidases, such as neutral endopeptidase 24.11 and APN, has been shown to be enhanced by designing prodrugs in which the compound is dimerized by the formation of a disulfide bridge. 23, 24 We used a similar approach to increase the bioavailability of the APA inhibitor NI929 by generating NI956, a dimer with a disulfide bridge able to cross the blood-brain barrier. In this symmetrical molecule, the thiol group of NI929 is engaged in the disulfide bridge, rendering it unavailable for interaction with the zinc atom present in the APA active site, which is essential for its catalytic activity. [31] [32] [33] However, our results showed that the disulfide bridge of the prodrug NI956 is cleaved in vitro by dithiothreitol and in vivo by brain reductases, generating 2 active molecules of NI929, which inhibit brain APA activity.
We showed that NI956, in the presence of dithiothreitol, inhibit recombinant mouse APA activity with an inhibitory potency 10× that of EC33. 8, 18 NI956 was also more selective than EC33 for APA, with an activity against purified human APN in vitro 3 orders of magnitude lower than that of EC33 and no affinity for other zinc metalloproteases involved in the production or metabolism of vasoactive peptides, such as ACE (angiotensin-converting enzyme) or ACE-2 (Table S1 ). In addition, this compound displayed no binding to AT 1 and AT 2 or to the endothelin A and B receptors known to be involved in BP regulation (Table S1 ).
We used DOCA-salt rats receiving a continuously administered mineralocorticoid analog and salt supplementation. DOCA-salt rats display brain APA/RAS hyperactivity, whereas the systemic RAS activity is depressed, explaining why this model is resistant to treatment with systemic RAS blockers. 34 Brain RAS hyperactivity in DOCA-salt rats results into increased AVP release and sympathetic neuron activity. 34 This justified to use central-acting APA inhibitor prodrug, NI956, to normalize brain APA/RAS hyperactivity, which in turn decreases systemic AVP release and BP.
In vivo, the intracerebroventricular, the intravenous, or the oral administration of NI956 into DOCA-salt rats significantly inhibited brain APA activity. These results suggest that NI956 is efficiently transported from the gastrointestinal tract to the bloodstream and then to the brain, where the disulfide bridge of NI956 was immediately cleaved by brain reductases to generate 2 active molecules of NI929, which inhibited brain APA activity. By contrast, normotensive WKY rats receiving NI956 by the intravenous or oral routes displayed no decrease in brain APA activity relative to saline-treated WKY rats.
The decrease in brain APA activity observed in hypertensive DOCA-salt rats orally treated with NI956 was correlated with a decrease in BP. Indeed, the oral administration of 4 mg/kg NI956 in hypertensive DOCA-salt rats significantly decreased MABP, between 3 and 10 hours after treatment, with an ED 50 of 0.53 mg/kg. In comparison, the oral administration of 50 mg/kg RB150/firibastat significantly decreased MABP, between 5 and 9 hours after treatment, with an ED 50 NI956 , therefore, appears to be a best-inclass molecule for BP normalization after oral administration in a salt-dependent model of hypertension. Consistent with previous studies performed with RB150/firibastat, 22 oral treatment with NI956 had no effect on the MABP of normotensive WKY rats or on heart rate in DOCA-salt and WKY rats.
The difference in the effects of NI956 on brain APA activity and arterial BP in normotensive WKY and hypertensive DOCA-salt rats may be due to the hyperactivity of the brain APA and RAS observed in DOCA-salt rats but not in normotensive WKY rats. Moreover, changes in the blood-brain barrier have been observed in rats with chronic hypertension 35 that might make it easier for NI956 to enter the brain in hypertensive rats than in normotensive rats.
Consistent with the decrease in brain APA activity and MABP observed 4 hours after oral treatment with NI956 in DOCA-salt rats, oral NI956 administration in DOCA-salt rats induced a decrease in plasma AVP levels 4 hours after treatment. This suggests that oral NI956 administration, by generating NI929 in the brain and blocking the formation of brain Ang III, acted like EC33 15, 36 to decrease the release of AVP from the posterior pituitary into the bloodstream, thereby increasing diuresis, which may participate to the BP decrease by reducing the size of fluid compartment.
Moreover, NI956 treatment in DOCA-salt rats improved natriuresis without modification of both plasma sodium and potassium levels. This is to compare with several different classes of antihypertensive agents used to treat hypertension, including ACE inhibitors and thiazide diuretics, which have been reported to modify plasma potassium levels, leading in some cases to plasma potassium imbalance and sudden death. [25] [26] [27] In conclusion, our study illustrates the high potency of oral NI956 treatment for normalizing brain APA hyperactivity and BP for several hours after a single administration, decreasing plasma AVP levels, and increasing diuresis and natriuresis, without affecting plasma sodium and potassium concentrations, at a dose one tenth that required for RB150/firibastat, in an experimental salt-dependent model of hypertension. A summary of characteristics and results of the 2 APA inhibitor prodrugs, NI956 and RB150/firibastat, is illustrated in Table  S2 . NI956 is therefore a best-in-class central-acting APA inhibitor prodrug, belonging to the same drug class as RB150/ firibastat, supporting the development of treatments targeting brain APA for hypertension treatment.
Perspectives
The prevalence of hypertension varies greatly among different racial/ethnic groups, with the highest rates seen in blacks (40.4%), compared with whites (27.4%), Hispanics (26.1%), and Asians (16.1%). 37 Resistant hypertension among blacks and Hispanics is associated with high salt sensitivity. Blacks exhibit a particular hormonal profile, with low levels of plasma renin activity and high plasma AVP levels, 38, 39 and they are resistant to systemic RAS blockers. Our results for DOCA-salt rats show that brain-penetrating APA inhibitors may constitute a promising treatment for these patients. RB150 40 Efficacy of RB150/firibastat in lowering BP was proven in all subgroup analyses, including age, sex, ethnic origin, and weight, 41 supporting the development of RB150/firibastat for hypertension in patients for whom optimal BP control is difficult to obtain with currently available antihypertensive treatments. It will be interesting to evaluate the efficacy of NI956/QGC006 in a similar population to confirm if it could act as a novel antihypertensive agent working at a much lower dose than RB150/firibastat.
